Research shows some people predisposed for recurrent C. difficile infection

University of Cincinnati (UC) researchers have found that some patients appear to be more predisposed for recurrent infection from the bacterium Clostridium difficile, or C. diff, and that it may advance to a more serious inflammatory condition in those individuals.

These findings are being presented via poster during , Monday, May 21, 2012, in San, Diego.

Mary Beth Yacyshyn, PhD, an adjunct assistant professor in division of , says researchers found that the C. diff surface layer proteins (SLP) produced a different set of proteins (cytokines) in samples from individuals with recurrent infection when compared to samples from individuals with an initial onset of the infection, indicating a more chronic , which is also seen in (IBD).

"Surface layer proteins of C. diff play a role in cell adhesion, the and the host's inflammatory response," Yacyshyn explains. "We wanted to see if purified SLP would induce immune responses in the samples from individuals who had their first documented episode of C. difficile and recurrent episodes."

Blood samples were taken from initial, recurrent and healthy patients and the (lymphocytes) were isolated and cultured for 48 hours with SLP from C. difficile.

Researchers found SLP stimulation produced a wide array of proteins, or cytokines, being secreted in all groups.

"However, patients with recurrent C. difficile infection produced a more inflammatory pattern of cytokines than did patients with an initial infection," she says. "We found that some levels of these cytokines were similar to those found in the comorbid case controls, suggesting that any patient hospitalized for an extended period may be exposed to C. difficile.

"Overall, we found that the cytokine response from recurrent patients is more indicative of a chronic inflammatory process, suggesting that the initial immune response may be crucial to clearing the infection. If, due to other underlying disease predispositions, genetics or current medications, a patient does not clear the infection, this may result in a chronic or systemic inflammatory response leading to continuous infection or re-infection."

Yacyshyn says this is the first step in many to target the C. diff infection at the cellular level for the best patient outcome.

"In knowing that these cells respond differently in different people, we may be able to tailor treatment and avoid the onset of a chronic condition," she says.

add to favorites email to friend print save as pdf

Related Stories

Doctors identify patients at high risk of C. difficile

Apr 01, 2009

Doctors have developed and validated a clinical prediction rule for recurrent Clostridium difficile (C. difficile) infection that was simple, reliable and accurate, and can be used to identify high-risk patients most likely t ...

Recommended for you

Recorded Ebola deaths top 7,000

5 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

9 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.